Successful target attainment of telavancin at elevated MICs: Fact or fiction?

摘要

Lodise et al. aimed to characterize the pharmacokinetics and pharmacodynamics of telavancin among patients with complicated skin and skin structure infections (cSSSIs) and various degrees of renal function (6). During evaluation, an area under the concentration-time curve (AUC)/MIC ratio of 219 or more was selected as the pharmacodynamic target. The authors concluded that all proposed dosing regimens would achieve a 93% or higher coverage in the population when the MIC is equal to 2 mg/liter (6).